BNO 5.26% 20.0¢ bionomics limited

"It is intended that the data from the ongoing BNC210 trial in...

  1. 912 Posts.
    lightbulb Created with Sketch. 95
    "It is intended that the data from the ongoing BNC210 trial in Agitation will be
    analysed by dose and by measures of exposure given the PTSD trial learnings.
    Consequently, this trial is anticipated to read out in Q2, 2019."
    "Greenhill & Co was appointed to conduct a thorough and independent
    review of the strategic options with an update expected to be announced in Q2CY2019 together with
    the results of the BNC210 Phase 2 clinical trial for the treatment of Agitation in the Elderly."
    https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSDYL4g2+zxb+v/V38LFiGug=

    So first top line results of the Agitation trial due by 30th June. Is to be reported at the same time as the Independent strategic review results by Greenhill & Co.
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.